|
Price: $71.3500
$0.25 
0.352%
|
| Day's High:
| $71.785
| Week Perf:
| -8.97 %
|
| Day's Low: |
$ 69.99 |
30 Day Perf: |
-4.73 % |
| Volume (M): |
730 |
52 Wk High: |
$ 80.28 |
| Volume (M$): |
$ 52,114 |
52 Wk Avg: |
$57.66 |
| Open: |
$70.81 |
52 Wk Low: |
$40.45 |
|
|
| Market Capitalization (Millions $) |
3,445 |
| Shares
Outstanding (Millions) |
48 |
| Employees |
900 |
| Revenues (TTM) (Millions $) |
297 |
| Net Income (TTM) (Millions $) |
-126 |
| Cash Flow (TTM) (Millions $) |
-11 |
| Capital Exp. (TTM) (Millions $) |
27 |
Glaukos Corp
Glaukos Corporation is a medical technology company that focuses on developing and commercializing products and procedures to treat glaucoma, one of the leading causes of blindness worldwide. It was founded in 1998 and is headquartered in San Clemente, California, United States.
Glaukos Corporation offers a broad range of innovative glaucoma treatments that are designed to offer safe, long-lasting, and effective relief to patients suffering from this debilitating eye disease. The company's flagship product is the iStent, which is the world's first micro-bypass stent approved for use in patients with mild to moderate open-angle glaucoma. This tiny stent is placed into the eye during a minimally invasive procedure, through which it helps to alleviate intraocular pressure by improving the drainage of fluid from the eye.
Beyond the iStent, Glaukos offers a suite of glaucoma products that leverage the company's expertise in micro-scale devices and implantable technologies. These products include the iStent Inject, a next-generation version of the iStent that offers increased flow through two stents, as well as the iStent SA, which is designed for use in patients who are undergoing cataract surgery.
In addition to its product offerings, Glaukos has a robust research and development program that is focused on advancing the field of glaucoma treatment. This includes a pipeline of novel devices, surgical systems, and drug-delivery technologies that aim to address unmet needs in the glaucoma market.
The company's strong growth in recent years has been driven by its ability to provide compelling solutions to a significant unmet need in the ophthalmology marketplace. In 2020, Glaukos generated revenues of $196 million, a7% increase from the previous year.
Overall, Glaukos Corporation is a leading player in the ophthalmology space, with a strong track record of innovation and a commitment to improving patients' lives. As the company continues to invest in research and development, it is well-positioned to remain a key player in the glaucoma market for years to come.
Company Address: One Glaukos Way Aliso Viejo 92656 CA
Company Phone Number: 367-9600 Stock Exchange / Ticker: NYSE GKOS
| GKOS is expected to report next financial results on November 02, 2023. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Fonar Corporation
In the recent fiscal period, Fonar Corporation, a prominent player in the Medical Equipment and Supplies sector, reported disappointing financial results. However, despite the challenges faced, there are reasons to be cautiously optimistic about the company's future performance. This article will provide an in-depth analysis of Fonar Corporation's financials and evaluate its potential for recovery.
Financial Performance
Fonar Corporation experienced a significant drop in its earnings per share (EPS) from $0.23 to -$1.16 compared to the same period last year. Meanwhile, its revenue showed moderate growth, with a 3.885% increase to $25.78 million. This growth, however, falls short of the 4.79% expected by the Medical Equipment and Supplies sector as a whole.
|
|
Precision Optics Corporation Inc
Precision Optics Corporation Inc (POCI) has experienced a slight increase in its stock value over the past week, rising by 0.66%. Additionally, its stock currently trades 6.5% above its 52-week low. These figures indicate positive performance for the company in the stock market.
Examining POCI's financial report for the fourth quarter of 2023, it is evident that the company faced a net loss per share of $-0.11. This represents a decline from the $0.08 per share profit reported in the previous year. However, despite the loss, POCI saw a 4.811% increase in revenue, reaching $5.02 million compared to the corresponding reporting period the previous year.
|
|
Heart Test Laboratories Inc
Heart Test Laboratories Inc, a medical device manufacturing company, recently released its financial results for the first quarter of the 2024 earnings season. The figures demonstrate a significant decrease in loss per share compared to the previous year, as well as an improvement in earnings per share. Although the revenue remained unchanged, the company reported a lower net shortfall compared to the same reporting season the previous year. This article aims to provide an overview of Heart Test Laboratories Inc's Q1 2024 financial results and analyze them within the context of recent stock performance.
Financial Results:
Heart Test Laboratories Inc reported a loss per share of $-0.13 in the first quarter of 2024, a considerable improvement from the loss per share of $-0.28 in the same reporting season the previous year. Additionally, the company's earnings per share increased from $-0.16 in the previous reporting season. Despite these positive developments, the revenue for Q1 2024 remained unchanged at $0.00 million, both compared to the same reporting season a year before and sequentially.
|
|
Sensasure Technologies Inc
Date: August 1, 2023
As the financial interval closing July 31, 2023 draws to a close, Sensasure Technologies Inc, a leading technology company, has achieved a significant milestone by reaching break-even at $0.00 per share. This marks an improvement from the same reporting period a year ago when the company also reported a break-even, and from the preceding reporting period.
However, while this is an encouraging development for Sensasure Technologies Inc, it is crucial to examine the context of the financial results to gain deeper insights.
|
|
Innovage Holding Corp
Innovage Holding Corp, a Medical Equipment and Supplies company, recently released its financial results for the fourth quarter of 2023. Despite reporting a loss of $0.08 per share, compared to $0.09 in the previous year, the company's revenue grew moderately by 2.322% to $176.87 million.
However, this revenue surge was lower than the average growth rate of 4.80% for the Medical Equipment and Supplies sector during the same period. Analysts believe that this slower growth may be due to a decline in demand, as evidenced by the decrease in accounts receivable to $24.3 million.
|
| Per Share |
Current |
| Earnings (TTM) |
-2.64 $ |
| Revenues (TTM) |
6.15 $
|
| Cash Flow (TTM) |
- |
| Cash |
6.29 $
|
| Book Value |
10.12 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-2.64 $
|
| Revenues (TTM) |
6.15 $ |
| Cash Flow (TTM) |
- |
| Cash |
6.29 $
|
| Book Value |
10.12 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
